No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[TITLE]Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million:
[TEXT]
ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new healthcare focused institutional investors with the potential to raise up to $104.5 million in gross proceeds, including initial upfront funding of $16.5 million and up to an additional $88.0 million upon the potential cash exercise of accompanying warrants at the election of the investors. The private placement was priced at a premium to the Company’s prior day’s closing stock price.

The financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.

Maxim Group LLC is acting as sole placement agent for the private placement.

Pursuant to terms of the securities purchase agreement, Quoin will issue an aggregate of 1,993,940 American Depository Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants, in accordance with the "Minimum Price" requirement as defined in the Nasdaq rules. The accompanying warrants will consist of four tranches:

Series H warrants to purchase up to 1,993,940 ADSs at an exercise price of $9.075 per ADS for an aggregate exercise price of up to $18.1 million. The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Company’s public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

Series I warrants to purchase up to 1,993,940 ADSs at an exercise price of $10.3125 per ADS for an aggregate exercise price of up to $20.6 million. The Series I warrants are immediately exercisable and expire as follows: 50% of the Series I warrants will expire on the earlier of (i) 30 days after the Company’s public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance; and the remaining 50% of Series I warrants will expire on the earlier of (i) 30 days after the Company’s public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

Series J warrants to purchase up to 1,993,940 ADSs at an exercise price of $12.375 per ADS for an aggregate exercise price of up to $24.7 million. The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

Series K warrants to purchase up to 1,993,940 ADSs at an exercise price of $12.375 per ADS for an aggregate exercise price of up to $24.7 million. The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Company’s sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance.

In lieu of ADSs, certain investors are purchasing pre-funded warrants at a combined purchase price of $8.2499 per pre-funded warrant and accompanying warrants, which equals the purchase price per ADS and accompanying warrants less $0.0001, which is in turn equal to the exercise price of each pre-funded warrant. The private placement is expected to close on or
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3164898/0/en/Quoin-Pharmaceuticals-Announces-Private-Placement-Financing-of-Up-to-104-5-Million.html


[TITLE]Global Protein Drugs Market to Reach $655.7 Billion by 2029:
[TEXT]
Boston, Oct. 10, 2025 (GLOBE NEWSWIRE) -- As demand for targeted, biologic-based treatments continues to grow, protein drugs are transforming how pharmaceutical companies address chronic, genetic, and life-threatening diseases. From monoclonal antibodies (mAbs) to peptide hormones and vaccines, global leaders such as AbbVie, Novo Nordisk and Sanofi are scaling next-generation platforms that deliver therapeutic precision, improved efficacy, and broader accessibility across healthcare systems.

According to the report, the increasing incidence of cancer, technological innovation in biologics production, and expanding biosimilar pipelines are reshaping the protein therapeutics landscape. The global market is expected to grow from $441.7 billion in 2024 to $655.7 billion by 2029, at a CAGR of 8.2%. While North America continues to dominate the global market, Europe and Asia-Pacific are emerging as high-opportunity regions for protein drug manufacturing and regulatory innovation. Manufacturers must balance affordability, scale, and sustainability to maximize long-term growth.

Market Insights and Strategic Trends Shaping Growth

Protein drugs are moving beyond specialty treatment into mainstream medicine, supported by scalable manufacturing platforms such as cell culture, microbial fermentation, and chemical synthesis. These technologies enable cost-effective production of mAbs, peptide antibiotics, and therapeutic enzymes, driving both market accessibility and therapy customization. Companies are investing in flexible facilities and hybrid platforms to improve production timelines and accommodate varied drug classes.

(Chapter 2: Market Overview; Chapter 6: Market Segment Analysis)

Venture capital, licensing deals, and multinational co-development programs are accelerating innovation across the protein drug value chain. Notable alliances and IPOs are supporting the development of AI-assisted protein modeling, biosimilar launch strategies, and data-driven drug optimization platforms. The growing prevalence of fusion proteins, cytokines, and advanced vaccines is attracting diversified investment portfolios aimed at expanding into underserved therapeutic areas.

(Chapter 3: Market Dynamics; Chapter 5: Emerging Technologies)

Strategically, leading pharmaceutical companies are prioritizing portfolio diversification and regional expansion. Dual-track approaches involve both organic R&D and M&A activity, with increased focus on low-cost biosimilar production, automated biomanufacturing, and high-potency biologics. Regulatory clarity in emerging economies is enabling faster market entry, while patent cliffs in the U.S. and Europe are opening windows for biosimilar competition.

(Chapter 7: Competitive Intelligence; Chapter 6: Market Segment Analysis)

Technological innovation remains central, particularly around continuous manufacturing, protein stabilization, and targeted drug delivery systems. The adoption of platform-based biologics pipelines and the integration of digital twins in manufacturing are helping optimize yield, reduce variability, and lower costs. Simultaneously, cell-free expression systems and AI-designed proteins are emerging as next-gen solutions in discovery and formulation.

(Chapter 5: Emerging Technologies; Chapter 7: Competitive Intelligence)

Sustainability is becoming a key differentiator, with major firms embedding ESG goals into their biologics strategies. This includes transitioning to green bioprocessing, reducing energy consumption in fermentation, and improving packaging efficiency. ESG scores are now playing a role in procurement decisions, investment ratings, and competitive positioning in regulated markets, especially as global healthcare systems emphasize environmental accountability.

(Chapter 8: Sustainability in the Protein Drug Market: ESG Perspective)

Report Synopsis

Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $409.2 billion Market size forecast $655.7 billion Growth rate CAGR of 8.2% for the forecast period of 2024-2029 Segments covered Type, Manufacturing Technology, and Region Regions covered North America, Asia-Pacific, Europe, Rest of the World Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, South America, and the Middle East and Africa Market drivers Advances in manufacturing technologies.

Product launches.

Increasing incidence of cancer.

Licensing and collaboration agreements.

Increasing number of approvals for mAb drugs.

Additional Insights:

• The first FDA-approved recombinant protein drug was Humulin (insulin), approved in 1982, marking a major breakthrough in biotechnology.

• A comprehensive database known as THPdb tracks all approved peptide and protein therapeutics.

• Currently, the FDA has approved hundreds of therapeutic protein drugs, which include widely used treatments such as insulin, growth hormone, Erythropoietin, various mAbs, and interferons.

Market leaders include:

AbbVie Inc .

Amgen Inc .

AstraZeneca

Bayer Ag

Bristol-Myers Squibb Co .

F. Hoffmann-La Roche Ltd .

Johnson & Johnson

Lilly

Merck & Co. Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc .

Regeneron Pharmaceuticals Inc .

Sanofi

Takeda Pharmaceutical Co. Ltd.

Get your copy of the report directly from BCC Research.

To request more information or complete your purchase, connect with us at info@bccresearch.com.

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3165063/0/en/Global-Protein-Drugs-Market-to-Reach-655-7-Billion-by-2029.html


[TITLE]Cannabis Market Trends and Company Analysis 2025-2033 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora, Jazz Pharma, Green Thumb Industries, Trulieve, Cresco Labs, Organigram, TerrAscend:
[TEXT]
Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Cannabis
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3164982/28124/en/Cannabis-Market-Trends-and-Company-Analysis-2025-2033-Featuring-Canopy-Growth-Tilray-Brands-Curaleaf-Aurora-Jazz-Pharma-Green-Thumb-Industries-Trulieve-Cresco-Labs-Organigram-TerrA.html


[TITLE]Clinical Stage Partnering Terms and Agreements in Pharma and Biotech: 1,775 Deals + SEC Contracts, Top 25 Dealmaker Profiles, 2020-2025:
[TEXT]
Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides a comprehensive, data-driven analysis of how and why companies engage in clinical-stage partnering agreements, as well as the financial and strategic terms shaping these collaborations. This essential industry resource delivers unparalleled insights into deal structures, negotiation dynamics, and financial considerations for clinical-stage drug development partnerships.

At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.

This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

Benchmarking deal structures and financial terms

Optimizing negotiation strategies

Assessing potential partners' flexibility

Identifying trends in clinical-stage partnerships

Why This Report is Essential for Dealmakers

Understanding the flexibility and negotiation strategies of potential partners is critical when structuring clinical-stage partnerships. While headline financial terms (e.g., upfront payments, milestones, royalties) provide a broad overview, contract documents reveal the actual triggers and conditions for these payments - details often missing from
[Source link]: https://www.globenewswire.com/news-release/2025/10/13/3165403/28124/en/Clinical-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech-1-775-Deals-SEC-Contracts-Top-25-Dealmaker-Profiles-2020-2025.html


===== Company info for companies mentioned in news =====

Company name: astrazeneca
symbol: AZN
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438815
name: astrazeneca
------------------------------------------------------------------

Company name: canopy growth
symbol: 11L.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438815
name: canopy growth
------------------------------------------------------------------

Company name: quoin pharmaceuticals
name: quoin pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=quoin+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: tilray brands
symbol: TLRY
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438816
name: tilray brands
------------------------------------------------------------------

================================================================================

[TITLE]Single-cell Analysis Market to Reach USD 12.29 Billion by 2032, Driven by Expanding Oncology Research and Advanced Genomics – SNS Insider:
[TEXT]
Austin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Single-cell Analysis Market Size & Growth Analysis

According to SNS Insider, the global Single-cell Analysis Market was valued at USD 3.90 billion in 2024 and is projected to reach USD 12.29 billion by 2032 growing at a CAGR of 13.61% over the forecast period of 2025-2032. This growth is driven by increasing use of single-cell analysis (SCA) in cancer research, precision medicine and drug discovery. The rising investment of biotechnology, the swift uptake of multi-omics tools, and growing demand for early disease detection drive market growth.

The consumables sector is the largest market segment, brought on by the requirement of assay kits, buffers, beads and cell isolation products as essential part of continued research flow. Concurrently, developments in cell isolation and technology for library preparation are opening new areas of opportunity in genomics and proteomics, including oncology and immunology.

Get free Sample Report of Single-cell Analysis Market: https://www.snsinsider.com/sample-request/3730

Single-cell Analysis Market Overview

single cells analysis is a valuable tool for exploring gene expression, epigenetic modification and protein interaction at the single-cell level. Compare to its conventional bulk readout counterparts that obscure cellular heterogeneity in the sample, SCA delivers high-content information relevant for disease mechanism study and biomarker discovery, as well as targeted therapy development.

The technology has proven itself as a powerful research tool in oncology, neurology, immunology and stem cell studies. Such quick uptake is backed by a well-developed ecosystem of biotech firms, research institutes and government-funded initiatives. Advances in microfluidics, droplet-based sequencing and next-generation informatics are also driving increased scale, throughput and accuracy.

Major Players in the Single-cell Analysis Market Include:

10x Genomics, Inc

BD Biosciences

Illumina Inc.

Thermo Fisher Scientific, Inc

Bio-Rad Laboratories

Fluidigm Corporation

Agilent Technologies

PerkinElmer

QIAGEN NV

Merck KGaA

Takara Bio

NanoString Technologies

Roche Diagnostics

Singleron Biotechnologies

Mission Bio

Parse Biosciences

Celsee, Inc.

Dolomite Bio

Cell Microsystems

Miltenyi Biotec

Single-cell Analysis Market Report Scope

Report Attributes Details Market Size in 2024 US$ 3.90 Billion Market Size by 2032 US$ 12.29 Billion CAGR CAGR of 13.61% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Key Segments By Product (Instruments, Consumables)

By Workflow (Single Cell Isolation & Library Preparation, Downstream Analysis, Data Analysis)

By Application (Cancer, Immunology, Neurology, Stem Cell, Non-Invasive Prenatal Diagnosis, In-Vitro Fertilization, Others)

By End User (Academic & Research Laboratories, Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostic Laboratories, Others) Regional Analysis/Coverage North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Single-cell Analysis Market Segment Insights

By Product

The Consumables segment held the largest market share in 2024, with 54.2%. Such dominance is attributed to the high consumption of isolation products, beads, buffers, and assay kits in single-cell research. There is continuous demand for these consumables in labs, which brings steady flow of revenues. With the development of personalized medicine, demand for high quality reagents and consistent consumable kits has surged.

By Workflow

The Single Cell Isolation & Library Preparation segment held 37.5% of the market share in 2024. Growing commercial availability of isolation technologies, such as FACS, MACS, microdissection, flow cytometry and microfluidics will boost adoption. These sophisticated workflows allow researchers to handle heterogeneous cell suspensions effectively, leading to innovations in genomics, transcriptomics, and proteomics.

By Application

The Cancer segment held the largest market share in 2024, 33.2%, and was projected to grow with a CAGR of 19.87% throughout the estimated period. The market for breast cancer is dominated by an increasing prevalence of the disease, demand for early diagnostics and rise in research on genetic variations. One of the most important applications of single-cell technologies is to uncover rare cell populations in cancer, to dissect tumor heterogeneity and to elucidate personalized therapeutic approaches.

By End User

Academic & Research Laboratories accounted 73.7% of share of the market in 2024. Universities and research institutes continue to act as the bedrock of single-cell technology adoption for basic research, biomarker finding and spatial genomics. CycMIST, a new tool created by Stony Brook University, demonstrates the continued development of tools in Research and Education.

Buy the Single-cell Analysis Market Report Now: https://www.snsinsider.com/checkout/3730

Regional Analysis

North America Takes the Lead Due to Robust Research Ecosystem

North America was the leading contributor to hyperimmune globulin market share in 2024 and is surpassing further growth due to large number of government funding programs, developed healthcare facilities as well as early technology adoption. In particular, the U.S. enjoys a competitive advantage in the form of National Institutes of Health (NIH) Programs, precision medicine programs and the presence of major industry stakeholders.

Asia Pacific Registers Fastest Growth

During 2025–2032, Asia Pacific is projected to expand at a CAGR of 19.9%. Key drivers are: Rapid modernization of healthcare systems, growing investment in diagnostics and a rising elderly population. The region, is poised to be the next big thing in this market as countries such as Japan, China and India are scaling up their genominal project and expanding its precision medicine outreach.

Recent Developments in the Single-cell Analysis Market

June 2025: 10x Genomics launched a new high-throughput single-cell sequencing platform designed to reduce per-sample costs and increase cell capture efficiency.

April 2025: Illumina partnered with a leading cancer research consortium to accelerate SCA-based biomarker discovery.

March 2025: Thermo Fisher expanded its single-cell consumables portfolio with advanced assay kits optimized for spatial genomics.

January 2025: Becton, Dickinson and Company introduced a next-gen flow cytometry platform tailored for single-cell applications in immunology.

Statistical Insights

Over 55% of SCA studies worldwide are focused on oncology and immunology.

Academic research accounts for nearly three-quarters of global SCA spending.

The U.S. leads in SCA patent filings and federal funding allocations.

Asia Pacific shows the fastest funding growth for genomics-based research.

The consumables segment drives recurring revenue, accounting for over 50% of total market sales.

Access Complete Report Details of Single-cell Analysis Market Analysis & Outlook: https://www.snsinsider.com/reports/single-cell-analysis-market-3730

[
[Source link]: https://www.globenewswire.com/news-release/2025/10/13/3165349/0/en/Single-cell-Analysis-Market-to-Reach-USD-12-29-Billion-by-2032-Driven-by-Expanding-Oncology-Research-and-Advanced-Genomics-SNS-Insider.html


[TITLE]Drug Discovery Market to Hit USD 146.25 Billion by 2033 Driven by AI Integration, Biotech Innovation, and Expanding Therapeutic Pipelines – SNS Insider:
[TEXT]
Austin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Drug Discovery Market Size & Growth Analysis

According to SNS Insider, the global Drug Discovery Market was valued at USD 71.95 billion in 2025E and is projected to reach USD 146.25 billion by 2033, growing at a CAGR of 9.29% during 2026–2033. The U.S. market, valued at USD 24.53 billion in 2025, is expected to reach USD 48.97 billion by 2033, supported by rapid advances in AI-driven target identification, biopharmaceutical innovation, regulatory incentives, and an expanding pipeline of novel therapies.

The market is experiencing robust momentum driven by a combination of cutting-edge technologies (including machine learning, CRISPR, and high-throughput screening), strong venture capital flows, and increasing prevalence of chronic and rare diseases globally. Increased collaborations between pharmaceutical companies and tech firms, along with expanding access to biologics, are further accelerating growth.

Get free Sample Report of Drug Discovery Market: https://www.snsinsider.com/sample-request/8522

Drug Discovery Market Overview

Drug discovery refers to the process of identifying new candidate medications, targeting specific biological pathways, and optimizing them for clinical use. Traditionally, this process has been lengthy and costly. However, the emergence of computational biology, AI-based predictive modeling, and structure-guided drug design has revolutionized how molecules are identified and advanced to clinical trials.

The U.S. continues to dominate this space thanks to its high R&D investment, strong regulatory frameworks, advanced academic and research institutions, and a well-established biotech ecosystem. Additionally, the growing integration of cloud-based platforms, multi-omics technologies, and automation is reducing development timelines and costs, bringing novel therapies to market faster.

Major Players in the Drug Discovery Market

Eli Lilly

Johnson & Johnson

AbbVie

Merck & Co.

Roche

Pfizer

AstraZeneca

Novartis

Bayer

GlaxoSmithKline (GSK)

Amgen

Sanofi

Bristol Myers Squibb

Abbott Laboratories

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Eisai Co., Ltd.

Takeda Pharmaceutical Company

Biogen

Drug Discovery Market Segment Insights

By Drug Type

Small molecules continue to dominate the market in 2025, accounting for 59.41% share, primarily due to their well-established manufacturing processes, cost efficiency, and ability to easily penetrate cells to target intracellular molecules. On the other hand, biologics are witnessing the fastest growth, registering a CAGR of 10.88%, driven by rising demand for targeted therapies and personalized medicine.

By Process

Target Identification & Validation held the largest market share of 33.47% in 2025, as it represents the foundational step in drug discovery, ensuring that therapeutic interventions are aimed at the right molecular targets. Conversely, Candidate Validation is expected to grow at the highest CAGR of 10.45%, propelled by the growing emphasis on predictive toxicology, safety profiling, and preclinical validation.

By Technology

High-Throughput Screening (HTS) contributed the largest market share of 41.29% in 2025 due to its critical role in rapidly identifying active compounds, antibodies, or genes that modulate specific biomolecular pathways. Bioinformatics, on the other hand, is anticipated to expand at the fastest CAGR of 11.22%, driven by the explosion of biological data and the growing use of computational tools for data interpretation.

By End-User

Pharmaceutical & Biotechnology Companies accounted for 52.56% of the market in 2025, primarily because they possess extensive R&D capabilities and financial resources to drive drug discovery and development. Meanwhile, Contract Research Organizations (CROs) are projected to grow at the fastest CAGR of 10.13%, as pharmaceutical firms increasingly outsource R&D activities to reduce operational costs and accelerate time-to-market.

Need Any Customization Research on Drug Discovery Market, Enquire Now: https://www.snsinsider.com/enquiry/8522

Regional Analysis

North America leads the global drug discovery market with a 41.27% share in 2025, driven by advanced pharmaceutical R&D infrastructure and strong biotech presence. More than 3,200 drug discovery programs were underway in the region as of 2025, across indications such as oncology, neurology and rare diseases.

The Asia Pacific drug discovery market is projected to grow at a CAGR of 9.82% during 2026–2033, making it the fastest-growing region globally. The expansion is supported by growing pharmaceutical R&D, rising biologics and targeted therapy pipelines, and favorable government policies.

Recent Developments in the Drug Discovery Market

In March 2025, Pfizer and an AI-driven biotech firm announced a strategic partnership to accelerate oncology drug discovery using deep learning platforms.

Roche launched an integrated data analytics suite to improve early-stage screening success rates.

AstraZeneca expanded its presence in Asia with a new R&D center focusing on precision medicine.

Johnson & Johnson unveiled positive Phase II data from its first AI-identified small molecule therapy.

Novartis announced a $1.5 billion investment to expand biologics research capabilities in the U.S.

Drug Discovery Market Report Scope

Report Attributes Details Market Size in 2025 USD 71.95 Billion Market Size by 2033 USD 146.25 Billion CAGR CAGR of 9.29% From 2026 to 2033 Base Year 2025 Forecast Period 2026-2033 Historical Data 2022-2024 Key Segments By Process (Target Identification & Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation, Others)

By Technology (High-Throughput Screening, Bioinformatics, Molecular Modeling & Simulation, Genomics, Proteomics, Others)

By Drug Type (Small Molecules, Biologics, Others)

By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Others) Regional Analysis/Coverage North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Buy the Drug Discovery Market Report Now: https://www.snsinsider.com/checkout/8522

Exclusive Sections of the Report (The USPs):

ACTIVE DRUG DISCOVERY PROGRAM INTELLIGENCE – helps you track the global distribution and growth of ongoing discovery programs by therapeutic area (oncology, neurology, rare diseases), highlighting where innovation and R&D funding are most concentrated.

– helps you track the global distribution and growth of ongoing discovery programs by therapeutic area (oncology, neurology, rare diseases), highlighting where innovation and R&D funding are most concentrated. TECHNOLOGY ADOPTION STATISTICS – helps you evaluate the penetration of high-throughput screening, AI, bioinformatics, genomics, and proteomics across discovery pipelines, revealing trends in automation, computational modeling, and digital transformation.

– helps you evaluate the penetration of high-throughput screening, AI, bioinformatics, genomics, and proteomics across discovery pipelines, revealing trends in automation, computational modeling, and digital transformation. AI–BIOINFORMATICS INTEGRATION INDEX – helps you measure the share of integrated AI/bioinformatics platforms adopted by pharmaceutical and biotech companies, indicating the maturity level of data-driven discovery ecosystems.

– helps you measure the share of integrated AI/bioinformatics platforms adopted by pharmaceutical and biotech companies, indicating the maturity level of data-driven discovery ecosystems. DRUG TYPE DISTRIBUTION MATRIX – helps you assess the evolving balance between small molecules, biologics, and advanced therapies (gene/cell therapies), along with the growth momentum of targeted and biologic candidates in discovery pipelines.

– helps you assess the evolving balance between small molecules, biologics, and advanced therapies (gene/cell therapies), along with the growth momentum of targeted and biologic candidates in discovery pipelines. END-USER PARTICIPATION ANALYTICS – helps you understand the engagement levels of pharmaceutical & biotechnology companies, CROs, and academic research institutions in global discovery programs, identifying collaboration and outsourcing trends.

– helps you understand the engagement levels of pharmaceutical & biotechnology companies, CROs, and academic research institutions in global discovery programs, identifying collaboration and outsourcing trends. TECHNOLOGY ADOPTION GROWTH RATE BENCHMARKS – helps you quantify the annual growth rate of new technology adoption in discovery processes, providing visibility into emerging innovation hotspots within the global drug discovery landscape.

Access Complete Report Details of Drug Discovery Market Analysis & Outlook: https://www.snsinsider.com/reports/drug-discovery-market-8522

[
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3164887/0/en/Drug-Discovery-Market-to-Hit-USD-146-25-Billion-by-2033-Driven-by-AI-Integration-Biotech-Innovation-and-Expanding-Therapeutic-Pipelines-SNS-Insider.html


[TITLE]Global Protein Drugs Market to Reach $655.7 Billion by 2029:
[TEXT]
Boston, Oct. 10, 2025 (GLOBE NEWSWIRE) -- As demand for targeted, biologic-based treatments continues to grow, protein drugs are transforming how pharmaceutical companies address chronic, genetic, and life-threatening diseases. From monoclonal antibodies (mAbs) to peptide hormones and vaccines, global leaders such as AbbVie, Novo Nordisk and Sanofi are scaling next-generation platforms that deliver therapeutic precision, improved efficacy, and broader accessibility across healthcare systems.

According to the report, the increasing incidence of cancer, technological innovation in biologics production, and expanding biosimilar pipelines are reshaping the protein therapeutics landscape. The global market is expected to grow from $441.7 billion in 2024 to $655.7 billion by 2029, at a CAGR of 8.2%. While North America continues to dominate the global market, Europe and Asia-Pacific are emerging as high-opportunity regions for protein drug manufacturing and regulatory innovation. Manufacturers must balance affordability, scale, and sustainability to maximize long-term growth.

Market Insights and Strategic Trends Shaping Growth

Protein drugs are moving beyond specialty treatment into mainstream medicine, supported by scalable manufacturing platforms such as cell culture, microbial fermentation, and chemical synthesis. These technologies enable cost-effective production of mAbs, peptide antibiotics, and therapeutic enzymes, driving both market accessibility and therapy customization. Companies are investing in flexible facilities and hybrid platforms to improve production timelines and accommodate varied drug classes.

(Chapter 2: Market Overview; Chapter 6: Market Segment Analysis)

Venture capital, licensing deals, and multinational co-development programs are accelerating innovation across the protein drug value chain. Notable alliances and IPOs are supporting the development of AI-assisted protein modeling, biosimilar launch strategies, and data-driven drug optimization platforms. The growing prevalence of fusion proteins, cytokines, and advanced vaccines is attracting diversified investment portfolios aimed at expanding into underserved therapeutic areas.

(Chapter 3: Market Dynamics; Chapter 5: Emerging Technologies)

Strategically, leading pharmaceutical companies are prioritizing portfolio diversification and regional expansion. Dual-track approaches involve both organic R&D and M&A activity, with increased focus on low-cost biosimilar production, automated biomanufacturing, and high-potency biologics. Regulatory clarity in emerging economies is enabling faster market entry, while patent cliffs in the U.S. and Europe are opening windows for biosimilar competition.

(Chapter 7: Competitive Intelligence; Chapter 6: Market Segment Analysis)

Technological innovation remains central, particularly around continuous manufacturing, protein stabilization, and targeted drug delivery systems. The adoption of platform-based biologics pipelines and the integration of digital twins in manufacturing are helping optimize yield, reduce variability, and lower costs. Simultaneously, cell-free expression systems and AI-designed proteins are emerging as next-gen solutions in discovery and formulation.

(Chapter 5: Emerging Technologies; Chapter 7: Competitive Intelligence)

Sustainability is becoming a key differentiator, with major firms embedding ESG goals into their biologics strategies. This includes transitioning to green bioprocessing, reducing energy consumption in fermentation, and improving packaging efficiency. ESG scores are now playing a role in procurement decisions, investment ratings, and competitive positioning in regulated markets, especially as global healthcare systems emphasize environmental accountability.

(Chapter 8: Sustainability in the Protein Drug Market: ESG Perspective)

Report Synopsis

Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $409.2 billion Market size forecast $655.7 billion Growth rate CAGR of 8.2% for the forecast period of 2024-2029 Segments covered Type, Manufacturing Technology, and Region Regions covered North America, Asia-Pacific, Europe, Rest of the World Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, South America, and the Middle East and Africa Market drivers Advances in manufacturing technologies.

Product launches.

Increasing incidence of cancer.

Licensing and collaboration agreements.

Increasing number of approvals for mAb drugs.

Additional Insights:

• The first FDA-approved recombinant protein drug was Humulin (insulin), approved in 1982, marking a major breakthrough in biotechnology.

• A comprehensive database known as THPdb tracks all approved peptide and protein therapeutics.

• Currently, the FDA has approved hundreds of therapeutic protein drugs, which include widely used treatments such as insulin, growth hormone, Erythropoietin, various mAbs, and interferons.

Market leaders include:

AbbVie Inc .

Amgen Inc .

AstraZeneca

Bayer Ag

Bristol-Myers Squibb Co .

F. Hoffmann-La Roche Ltd .

Johnson & Johnson

Lilly

Merck & Co. Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc .

Regeneron Pharmaceuticals Inc .

Sanofi

Takeda Pharmaceutical Co. Ltd.

Get your copy of the report directly from BCC Research.

To request more information or complete your purchase, connect with us at info@bccresearch.com.

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3165063/0/en/Global-Protein-Drugs-Market-to-Reach-655-7-Billion-by-2029.html


[TITLE]Precision Medicine Market Size Booms at 16.35% CAGR, Expected to Reach USD 463.11 Billion by 2034:
[TEXT]
Ottawa, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The global precision medicine
[Source link]: https://www.globenewswire.com/news-release/2025/10/10/3164977/0/en/Precision-Medicine-Market-Size-Booms-at-16-35-CAGR-Expected-to-Reach-USD-463-11-Billion-by-2034.html


===== Company info for companies mentioned in news =====

Company name: ai technology group
symbol: S13.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438823
name: ai technology group
------------------------------------------------------------------

Company name: biogen
symbol: BIIB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438824
name: biogen
------------------------------------------------------------------

Company name: stoke therapeutics
symbol: STOK
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438824
name: stoke therapeutics
------------------------------------------------------------------

Company name: transgene
symbol: TNG.PA
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1760438825
name: transgene
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

